SALT LAKE CITY, March 31, 2021 /PRNewswire/ -- The CEO
of Co-Diagnostics, Inc. (Nasdaq: CODX), a
molecular diagnostics company with a unique, patented platform for
the development of diagnostic tests, appeared yesterday on Yahoo!
Finance to comment on the Company's recently-released FY2020
earnings report, and to discuss its going-forward strategy as the
world struggles to achieve normalization.
Co-Diagnostics CEO Dwight Egan
remarked, "We believe that the future of gold-standard PCR
diagnostics will be defined by the convenience of at-home and
point-of-care testing, which will be critical in achieving
normalization. Our new platform, currently in development and
subject to regulatory approval, will empower individuals and
organizations to know their COVID-19 status quickly and accurately,
with do-it-yourself tests that could be performed in multiple
settings. We also believe that achieving normalcy will require a
strong reliance on continued testing to augment proliferation of
the COVID-19 vaccines, which we believe may take years to fully
administer on a global scale.
"2020 was a pivotal year for Co-Diagnostics as we built a global
distributor network that will provide a strong foundation for our
continued success. As we now rapidly add to our menu of diagnostic
testing products for infectious diseases that kill millions of
people every year, in addition to developing our liquid biopsy
vertical and continuing to provide our much-needed COVID-19
products, Co-Diagnostics expects to be prepared for the future with
the next generation of gold-standard PCR devices and tests for
at-home and point-of-care settings."
The interview with Yahoo! Finance can be found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that develops,
manufactures and markets a new, state-of-the-art diagnostics
technology. The Company's technology is utilized for tests that are
designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary
technology to design specific tests to locate genetic markers for
use in industries other than infectious disease and license the use
of those tests to specific customers.
Forward-Looking Statements:
This press release
contains forward-looking statements. Forward-looking statements can
be identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions.
Forward-looking statements in this release include statements
regarding the (i) use of funding proceeds, (ii) expansion of
product distribution, (iii) acceleration of initiatives in liquid
biopsy and SNP detection, (iv) use of the Company's liquid biopsy
tests by laboratories, (v) capital resources and runway needed to
advance the Company's products and markets, (vi) increased sales in
the near-term, (vii) flexibility in managing the Company's balance
sheet, (viii) anticipation of business expansion, and (ix) benefits
in research and worldwide accessibility of the CoPrimer technology
and its cost-saving and scientific advantages. Forward-looking
statements are subject to inherent uncertainties, risks and changes
in circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to rely
on any forward-looking statements. Any forward-looking statement
made by the Company in this press release is based only on
information currently available to the Company and speaks only as
of the date on which it is made. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-ceo-discusses-company-strategy-for-the-future-with-yahoo-finance-301259662.html
SOURCE Co-Diagnostics